---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-179817"
form_type: "8-K"
ticker: "CDXS"
cik: "0001200375"
company_name: "CODEXIS, INC."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:52:33.135480+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Codexis Q2 revenue $15.3M beats consensus; net loss narrows to $13.3M from $22.8M YoY

## Summary
- Revenue $15.3M, beating $14.1M analyst consensus; net loss $13.3M ($0.16/sh) vs $22.8M ($0.32/sh) YoY.
- Product gross margin improved to 72% from 45% YoY on shift to more profitable products.
- Raised $27.3M via ATM and Innovatus loan; cash and investments balance $66.3M at Q2 end.
- ECO Synthesis platform: over 30 opportunities, 6 presentations at TIDES USA, 3 CDMO collaborations.
- Appointed Cynthia Collins (CEO of Nutcracker Therapeutics) to Board of Directors in April 2025.

## SEC filing metadata
- accession: 0001193125-25-179817
- form_type: 8-K
- ticker: CDXS
- cik: 0001200375
- company_name: CODEXIS, INC.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1200375/000119312525179817/0001193125-25-179817-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1200375/000119312525179817/d940510d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-179817
- JSON: https://secwatch.observer/filing/0001193125-25-179817.json
- Plain text: https://secwatch.observer/filing/0001193125-25-179817.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.